Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2012-11

AUTHORS

John F. R. Robertson, Justin P. O. Lindemann, Antonio Llombart-Cussac, Janusz Rolski, David Feltl, John Dewar, Laura Emerson, Andrew Dean, Matthew J. Ellis

ABSTRACT

Fulvestrant fIRst-line Study comparing endocrine Treatments is a phase II, randomized, open-label study comparing fulvestrant 500 mg with anastrozole 1 mg as first-line endocrine therapy for postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer. At data cut-off, only 36 % of patients had progressed and the median time to progression (TTP) had not been reached for fulvestrant. Here, we report follow-up data for TTP for fulvestrant 500 mg versus anastrozole 1 mg. Key inclusion criteria were postmenopausal women with estrogen receptor-positive and/or progesterone receptor-positive locally advanced or metastatic breast cancer and no prior endocrine therapy. Key exclusion criteria were presence of life-threatening metastases and prior treatment with a non-approved drug. Fulvestrant was administered 500 mg/month plus 500 mg on day 14 of month 1; anastrozole was administered 1 mg/day. TTP was defined by modified Response Evaluation Criteria in Solid Tumors v1.0 before data cut-off for the primary analysis, and investigator opinion after data cut-off. Best overall response to subsequent therapy and serious adverse events are also reported. In total, 205 patients received fulvestrant 500 mg (n = 102) or anastrozole (n = 103). Follow-up analysis was performed when 79.5 % of patients had discontinued study treatment. Median TTP was 23.4 months for fulvestrant versus 13.1 months for anastrozole; a 34 % reduction in risk of progression (hazard ratio 0.66; 95 % confidence interval: 0.47, 0.92; P = 0.01). Best overall response to subsequent therapy and clinical benefit rate for subsequent endocrine therapy was similar between the treatment groups. No new safety concerns for fulvestrant 500 mg were documented. These longer-term, follow-up results confirm efficacy benefit for fulvestrant 500 mg versus anastrozole as first-line endocrine therapy for HR+ advanced breast cancer in terms of TTP, and, importantly, show similar best overall response rates to subsequent endocrine therapy. More... »

PAGES

503-511

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10549-012-2192-4

DOI

http://dx.doi.org/10.1007/s10549-012-2192-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1032719812

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23065000


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Hormonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Estradiol", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nitriles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Triazoles", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Royal Derby Hospital", 
          "id": "https://www.grid.ac/institutes/grid.413619.8", 
          "name": [
            "Division of Breast Surgery, Graduate Entry Medicine & Health School (GEMS), University of Nottingham, Royal Derby Hospital, Uttoxeter Road, DE22 3DT, Derby, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Robertson", 
        "givenName": "John F. R.", 
        "id": "sg:person.07764637207.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07764637207.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Alderley Park, Macclesfield, Cheshire, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lindemann", 
        "givenName": "Justin P. O.", 
        "id": "sg:person.01340372725.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340372725.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital Universitari Arnau de Vilanova", 
          "id": "https://www.grid.ac/institutes/grid.411443.7", 
          "name": [
            "Hospital Arnau de Vilanova, L\u00e9rida, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Llombart-Cussac", 
        "givenName": "Antonio", 
        "id": "sg:person.01202144642.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202144642.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Centrum Onkologii, Instytut im M. Sk\u0142odowskiej-Curie, Krak\u00f3w, Poland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rolski", 
        "givenName": "Janusz", 
        "id": "sg:person.01267031766.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01267031766.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "FNsP Ostrava, Radioterapeutick\u00e1 klinika, Ostrava-Poruba, Czech Republic"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Feltl", 
        "givenName": "David", 
        "id": "sg:person.01136166174.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136166174.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ninewells Hospital", 
          "id": "https://www.grid.ac/institutes/grid.416266.1", 
          "name": [
            "Department of Oncology, Ninewells Hospital and Medical School, Dundee, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dewar", 
        "givenName": "John", 
        "id": "sg:person.0622546425.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0622546425.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Charnwood, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Emerson", 
        "givenName": "Laura", 
        "id": "sg:person.01252414574.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01252414574.67"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Alderley Park, Macclesfield, Cheshire, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dean", 
        "givenName": "Andrew", 
        "id": "sg:person.01320527774.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320527774.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Washington University in St. Louis", 
          "id": "https://www.grid.ac/institutes/grid.4367.6", 
          "name": [
            "Washington University School of Medicine, St Louis, MO, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ellis", 
        "givenName": "Matthew J.", 
        "id": "sg:person.012333564657.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012333564657.16"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1200/jco.2010.28.8415", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004144759"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.11468", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007461265"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2004.02.112", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008461339"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clbc.2011.02.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016383117"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.21.1136", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017723747"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-200443080-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022973683", 
          "https://doi.org/10.2165/00003088-200443080-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-200443080-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022973683", 
          "https://doi.org/10.2165/00003088-200443080-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.12-7-774", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025436995"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-010-1022-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028916628", 
          "https://doi.org/10.1007/s10549-010-1022-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-010-1022-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028916628", 
          "https://doi.org/10.1007/s10549-010-1022-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-004-4776-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031540377", 
          "https://doi.org/10.1007/s10549-004-4776-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/92.3.205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032301848"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdq249", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038899124"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.14.4659", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043274143"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(20011101)92:9<2247::aid-cncr1570>3.0.co;2-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044474547"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2002.10.057", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203147"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2002.10.058", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203148"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2003.04.194", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203568"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2000.18.22.3748", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074728219"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2000.18.22.3758", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074728220"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074881954", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077661065", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-11", 
    "datePublishedReg": "2012-11-01", 
    "description": "Fulvestrant fIRst-line Study comparing endocrine Treatments is a phase II, randomized, open-label study comparing fulvestrant 500 mg with anastrozole 1 mg as first-line endocrine therapy for postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer. At data cut-off, only 36 % of patients had progressed and the median time to progression (TTP) had not been reached for fulvestrant. Here, we report follow-up data for TTP for fulvestrant 500 mg versus anastrozole 1 mg. Key inclusion criteria were postmenopausal women with estrogen receptor-positive and/or progesterone receptor-positive locally advanced or metastatic breast cancer and no prior endocrine therapy. Key exclusion criteria were presence of life-threatening metastases and prior treatment with a non-approved drug. Fulvestrant was administered 500 mg/month plus 500 mg on day 14 of month 1; anastrozole was administered 1 mg/day. TTP was defined by modified Response Evaluation Criteria in Solid Tumors v1.0 before data cut-off for the primary analysis, and investigator opinion after data cut-off. Best overall response to subsequent therapy and serious adverse events are also reported. In total, 205 patients received fulvestrant 500 mg (n = 102) or anastrozole (n = 103). Follow-up analysis was performed when 79.5 % of patients had discontinued study treatment. Median TTP was 23.4 months for fulvestrant versus 13.1 months for anastrozole; a 34 % reduction in risk of progression (hazard ratio 0.66; 95 % confidence interval: 0.47, 0.92; P = 0.01). Best overall response to subsequent therapy and clinical benefit rate for subsequent endocrine therapy was similar between the treatment groups. No new safety concerns for fulvestrant 500 mg were documented. These longer-term, follow-up results confirm efficacy benefit for fulvestrant 500 mg versus anastrozole as first-line endocrine therapy for HR+ advanced breast cancer in terms of TTP, and, importantly, show similar best overall response rates to subsequent endocrine therapy.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10549-012-2192-4", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1092777", 
        "issn": [
          "0167-6806", 
          "1573-7217"
        ], 
        "name": "Breast Cancer Research and Treatment", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "136"
      }
    ], 
    "name": "Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized \u2018FIRST\u2019 study", 
    "pagination": "503-511", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "9bdf9e6e09f4bec14a08ad590cf38961eac493fe127adbfe57980c8d6cea9305"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23065000"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8111104"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10549-012-2192-4"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1032719812"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10549-012-2192-4", 
      "https://app.dimensions.ai/details/publication/pub.1032719812"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T20:47", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8684_00000513.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs10549-012-2192-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10549-012-2192-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10549-012-2192-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10549-012-2192-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10549-012-2192-4'


 

This table displays all metadata directly associated to this object as RDF triples.

243 TRIPLES      21 PREDICATES      59 URIs      31 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10549-012-2192-4 schema:about N039c019e2f554162993b54593e8a0a91
2 N040ea268f2664891a6019f09a72e79dd
3 N21cc602a9f994e48b4181a946625c41d
4 N2ab6030f882f481d8a82425007c02f62
5 N4264ec17fd934a92aa51c0a96c6f632b
6 N4e55072bb2ae4a07a185288c93f0143b
7 N99bc560e0daf42d8a457ccaacbff07f9
8 Nb330030b40364804b3d6f04e28d25a2e
9 Ne3a9e35d42614cb5b30859f01119e16b
10 Neb7c93b995f34b60af66405195a5b6d3
11 anzsrc-for:11
12 anzsrc-for:1103
13 schema:author N1d55df7c92ff404cab44a821cacac75c
14 schema:citation sg:pub.10.1007/s10549-004-4776-0
15 sg:pub.10.1007/s10549-010-1022-9
16 sg:pub.10.2165/00003088-200443080-00003
17 https://app.dimensions.ai/details/publication/pub.1074881954
18 https://app.dimensions.ai/details/publication/pub.1077661065
19 https://doi.org/10.1002/1097-0142(20011101)92:9<2247::aid-cncr1570>3.0.co;2-y
20 https://doi.org/10.1002/cncr.11468
21 https://doi.org/10.1016/j.clbc.2011.02.002
22 https://doi.org/10.1093/annonc/mdq249
23 https://doi.org/10.1093/jnci/92.3.205
24 https://doi.org/10.1200/jco.2000.18.22.3748
25 https://doi.org/10.1200/jco.2000.18.22.3758
26 https://doi.org/10.1200/jco.2002.10.057
27 https://doi.org/10.1200/jco.2002.10.058
28 https://doi.org/10.1200/jco.2003.04.194
29 https://doi.org/10.1200/jco.2004.02.112
30 https://doi.org/10.1200/jco.2007.14.4659
31 https://doi.org/10.1200/jco.2008.21.1136
32 https://doi.org/10.1200/jco.2010.28.8415
33 https://doi.org/10.1634/theoncologist.12-7-774
34 schema:datePublished 2012-11
35 schema:datePublishedReg 2012-11-01
36 schema:description Fulvestrant fIRst-line Study comparing endocrine Treatments is a phase II, randomized, open-label study comparing fulvestrant 500 mg with anastrozole 1 mg as first-line endocrine therapy for postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer. At data cut-off, only 36 % of patients had progressed and the median time to progression (TTP) had not been reached for fulvestrant. Here, we report follow-up data for TTP for fulvestrant 500 mg versus anastrozole 1 mg. Key inclusion criteria were postmenopausal women with estrogen receptor-positive and/or progesterone receptor-positive locally advanced or metastatic breast cancer and no prior endocrine therapy. Key exclusion criteria were presence of life-threatening metastases and prior treatment with a non-approved drug. Fulvestrant was administered 500 mg/month plus 500 mg on day 14 of month 1; anastrozole was administered 1 mg/day. TTP was defined by modified Response Evaluation Criteria in Solid Tumors v1.0 before data cut-off for the primary analysis, and investigator opinion after data cut-off. Best overall response to subsequent therapy and serious adverse events are also reported. In total, 205 patients received fulvestrant 500 mg (n = 102) or anastrozole (n = 103). Follow-up analysis was performed when 79.5 % of patients had discontinued study treatment. Median TTP was 23.4 months for fulvestrant versus 13.1 months for anastrozole; a 34 % reduction in risk of progression (hazard ratio 0.66; 95 % confidence interval: 0.47, 0.92; P = 0.01). Best overall response to subsequent therapy and clinical benefit rate for subsequent endocrine therapy was similar between the treatment groups. No new safety concerns for fulvestrant 500 mg were documented. These longer-term, follow-up results confirm efficacy benefit for fulvestrant 500 mg versus anastrozole as first-line endocrine therapy for HR+ advanced breast cancer in terms of TTP, and, importantly, show similar best overall response rates to subsequent endocrine therapy.
37 schema:genre research_article
38 schema:inLanguage en
39 schema:isAccessibleForFree false
40 schema:isPartOf N389b5dbfff14411ba1795c01486fd123
41 N5f6ffb9ed8194944924f64b02726f952
42 sg:journal.1092777
43 schema:name Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study
44 schema:pagination 503-511
45 schema:productId N249ad4d91f114f3bbacd0b3046853013
46 N41a944e30ce6411a8596d7ba0831a642
47 N4448d51e649a49e8b21c90f74f6447dc
48 Nbf2b1b62b2f646b897eaddbe8efc1f30
49 Nda3ae8be574949a9aef7798e2e765b28
50 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032719812
51 https://doi.org/10.1007/s10549-012-2192-4
52 schema:sdDatePublished 2019-04-10T20:47
53 schema:sdLicense https://scigraph.springernature.com/explorer/license/
54 schema:sdPublisher N18026929e5fd496bad7f6aa71a36673c
55 schema:url http://link.springer.com/10.1007%2Fs10549-012-2192-4
56 sgo:license sg:explorer/license/
57 sgo:sdDataset articles
58 rdf:type schema:ScholarlyArticle
59 N039c019e2f554162993b54593e8a0a91 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
60 schema:name Estradiol
61 rdf:type schema:DefinedTerm
62 N040ea268f2664891a6019f09a72e79dd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
63 schema:name Antineoplastic Agents, Hormonal
64 rdf:type schema:DefinedTerm
65 N18026929e5fd496bad7f6aa71a36673c schema:name Springer Nature - SN SciGraph project
66 rdf:type schema:Organization
67 N18b7a7e88daa40c29010e00aa39b097d rdf:first sg:person.01340372725.62
68 rdf:rest N6403f86884f04d9eac6868b756311cf3
69 N1d55df7c92ff404cab44a821cacac75c rdf:first sg:person.07764637207.20
70 rdf:rest N18b7a7e88daa40c29010e00aa39b097d
71 N21cc602a9f994e48b4181a946625c41d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Neoplasm Staging
73 rdf:type schema:DefinedTerm
74 N249ad4d91f114f3bbacd0b3046853013 schema:name nlm_unique_id
75 schema:value 8111104
76 rdf:type schema:PropertyValue
77 N2ab6030f882f481d8a82425007c02f62 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Humans
79 rdf:type schema:DefinedTerm
80 N389b5dbfff14411ba1795c01486fd123 schema:issueNumber 2
81 rdf:type schema:PublicationIssue
82 N41a944e30ce6411a8596d7ba0831a642 schema:name readcube_id
83 schema:value 9bdf9e6e09f4bec14a08ad590cf38961eac493fe127adbfe57980c8d6cea9305
84 rdf:type schema:PropertyValue
85 N4264ec17fd934a92aa51c0a96c6f632b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Triazoles
87 rdf:type schema:DefinedTerm
88 N4448d51e649a49e8b21c90f74f6447dc schema:name doi
89 schema:value 10.1007/s10549-012-2192-4
90 rdf:type schema:PropertyValue
91 N458040d718d74ef998a98e366e020070 schema:name Centrum Onkologii, Instytut im M. Skłodowskiej-Curie, Kraków, Poland
92 rdf:type schema:Organization
93 N4e55072bb2ae4a07a185288c93f0143b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Treatment Outcome
95 rdf:type schema:DefinedTerm
96 N5f6ffb9ed8194944924f64b02726f952 schema:volumeNumber 136
97 rdf:type schema:PublicationVolume
98 N6223a407e75f4aa7a59c1493491268d2 rdf:first sg:person.01252414574.67
99 rdf:rest N7000298f572e4d878db98bd3dde8f809
100 N6403f86884f04d9eac6868b756311cf3 rdf:first sg:person.01202144642.66
101 rdf:rest Nd59e17279c534f84b16feda24f1cdc5b
102 N6434a6df85fd4916863782ab4e3d3216 rdf:first sg:person.012333564657.16
103 rdf:rest rdf:nil
104 N6669bd882eca44d2a76fd1a8dd47f545 rdf:first sg:person.01136166174.79
105 rdf:rest N94d5f899286441b3a9a55f60e42c35f7
106 N7000298f572e4d878db98bd3dde8f809 rdf:first sg:person.01320527774.13
107 rdf:rest N6434a6df85fd4916863782ab4e3d3216
108 N94d5f899286441b3a9a55f60e42c35f7 rdf:first sg:person.0622546425.10
109 rdf:rest N6223a407e75f4aa7a59c1493491268d2
110 N99bc560e0daf42d8a457ccaacbff07f9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Breast Neoplasms
112 rdf:type schema:DefinedTerm
113 Nb330030b40364804b3d6f04e28d25a2e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Follow-Up Studies
115 rdf:type schema:DefinedTerm
116 Nbf2b1b62b2f646b897eaddbe8efc1f30 schema:name pubmed_id
117 schema:value 23065000
118 rdf:type schema:PropertyValue
119 Nc749a3a8055445079a4173e552a0e296 schema:name FNsP Ostrava, Radioterapeutická klinika, Ostrava-Poruba, Czech Republic
120 rdf:type schema:Organization
121 Nd59e17279c534f84b16feda24f1cdc5b rdf:first sg:person.01267031766.41
122 rdf:rest N6669bd882eca44d2a76fd1a8dd47f545
123 Nda3ae8be574949a9aef7798e2e765b28 schema:name dimensions_id
124 schema:value pub.1032719812
125 rdf:type schema:PropertyValue
126 Ne3a9e35d42614cb5b30859f01119e16b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Nitriles
128 rdf:type schema:DefinedTerm
129 Neb7c93b995f34b60af66405195a5b6d3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Female
131 rdf:type schema:DefinedTerm
132 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
133 schema:name Medical and Health Sciences
134 rdf:type schema:DefinedTerm
135 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
136 schema:name Clinical Sciences
137 rdf:type schema:DefinedTerm
138 sg:journal.1092777 schema:issn 0167-6806
139 1573-7217
140 schema:name Breast Cancer Research and Treatment
141 rdf:type schema:Periodical
142 sg:person.01136166174.79 schema:affiliation Nc749a3a8055445079a4173e552a0e296
143 schema:familyName Feltl
144 schema:givenName David
145 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136166174.79
146 rdf:type schema:Person
147 sg:person.01202144642.66 schema:affiliation https://www.grid.ac/institutes/grid.411443.7
148 schema:familyName Llombart-Cussac
149 schema:givenName Antonio
150 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202144642.66
151 rdf:type schema:Person
152 sg:person.012333564657.16 schema:affiliation https://www.grid.ac/institutes/grid.4367.6
153 schema:familyName Ellis
154 schema:givenName Matthew J.
155 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012333564657.16
156 rdf:type schema:Person
157 sg:person.01252414574.67 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
158 schema:familyName Emerson
159 schema:givenName Laura
160 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01252414574.67
161 rdf:type schema:Person
162 sg:person.01267031766.41 schema:affiliation N458040d718d74ef998a98e366e020070
163 schema:familyName Rolski
164 schema:givenName Janusz
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01267031766.41
166 rdf:type schema:Person
167 sg:person.01320527774.13 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
168 schema:familyName Dean
169 schema:givenName Andrew
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320527774.13
171 rdf:type schema:Person
172 sg:person.01340372725.62 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
173 schema:familyName Lindemann
174 schema:givenName Justin P. O.
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340372725.62
176 rdf:type schema:Person
177 sg:person.0622546425.10 schema:affiliation https://www.grid.ac/institutes/grid.416266.1
178 schema:familyName Dewar
179 schema:givenName John
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0622546425.10
181 rdf:type schema:Person
182 sg:person.07764637207.20 schema:affiliation https://www.grid.ac/institutes/grid.413619.8
183 schema:familyName Robertson
184 schema:givenName John F. R.
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07764637207.20
186 rdf:type schema:Person
187 sg:pub.10.1007/s10549-004-4776-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031540377
188 https://doi.org/10.1007/s10549-004-4776-0
189 rdf:type schema:CreativeWork
190 sg:pub.10.1007/s10549-010-1022-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028916628
191 https://doi.org/10.1007/s10549-010-1022-9
192 rdf:type schema:CreativeWork
193 sg:pub.10.2165/00003088-200443080-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022973683
194 https://doi.org/10.2165/00003088-200443080-00003
195 rdf:type schema:CreativeWork
196 https://app.dimensions.ai/details/publication/pub.1074881954 schema:CreativeWork
197 https://app.dimensions.ai/details/publication/pub.1077661065 schema:CreativeWork
198 https://doi.org/10.1002/1097-0142(20011101)92:9<2247::aid-cncr1570>3.0.co;2-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1044474547
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1002/cncr.11468 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007461265
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1016/j.clbc.2011.02.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016383117
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1093/annonc/mdq249 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038899124
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1093/jnci/92.3.205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032301848
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1200/jco.2000.18.22.3748 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074728219
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1200/jco.2000.18.22.3758 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074728220
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1200/jco.2002.10.057 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203147
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1200/jco.2002.10.058 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203148
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1200/jco.2003.04.194 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203568
217 rdf:type schema:CreativeWork
218 https://doi.org/10.1200/jco.2004.02.112 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008461339
219 rdf:type schema:CreativeWork
220 https://doi.org/10.1200/jco.2007.14.4659 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043274143
221 rdf:type schema:CreativeWork
222 https://doi.org/10.1200/jco.2008.21.1136 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017723747
223 rdf:type schema:CreativeWork
224 https://doi.org/10.1200/jco.2010.28.8415 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004144759
225 rdf:type schema:CreativeWork
226 https://doi.org/10.1634/theoncologist.12-7-774 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025436995
227 rdf:type schema:CreativeWork
228 https://www.grid.ac/institutes/grid.411443.7 schema:alternateName Hospital Universitari Arnau de Vilanova
229 schema:name Hospital Arnau de Vilanova, Lérida, Spain
230 rdf:type schema:Organization
231 https://www.grid.ac/institutes/grid.413619.8 schema:alternateName Royal Derby Hospital
232 schema:name Division of Breast Surgery, Graduate Entry Medicine & Health School (GEMS), University of Nottingham, Royal Derby Hospital, Uttoxeter Road, DE22 3DT, Derby, UK
233 rdf:type schema:Organization
234 https://www.grid.ac/institutes/grid.416266.1 schema:alternateName Ninewells Hospital
235 schema:name Department of Oncology, Ninewells Hospital and Medical School, Dundee, UK
236 rdf:type schema:Organization
237 https://www.grid.ac/institutes/grid.417815.e schema:alternateName AstraZeneca (United Kingdom)
238 schema:name AstraZeneca, Alderley Park, Macclesfield, Cheshire, UK
239 AstraZeneca, Charnwood, UK
240 rdf:type schema:Organization
241 https://www.grid.ac/institutes/grid.4367.6 schema:alternateName Washington University in St. Louis
242 schema:name Washington University School of Medicine, St Louis, MO, USA
243 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...